
Opinion|Videos|February 7, 2025
Decision-Making and Evidence Evaluation of Biosimilars
A panelist discusses how their institution prioritizes cost savings and reliable supply chain considerations when selecting biosimilars for formulary inclusion, while also weighing switching study evidence, addressing stakeholder concerns through education, and implementing protocols to overcome barriers such as electronic health record integration and prior authorization challenges.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What characteristics (eg, cost, availability, accessibility, etc) of biosimilars are most important to your institution when deciding which agents to stock or keep on the formulary?
- What role do biosimilar switching studies play in this decision?
- In your experience, what are common barriers to implementing biosimilars at your institution?
- What strategies has your institution implemented to overcome the barriers to adopting biosimilars?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Studies of tafasitamab and epcoritamab
2
Dosing schedules of combination approaches
3
States push for new PBM reporting rules | PBMI 2026
4
A conversation with Julia S. Feldman, Ph.D., about taking impairment and context into consideration when diagnosing preschoolers with ADHD
5























